The estimated Net Worth of James F Iii Oliviero is at least $7.82 Milión dollars as of 26 June 2024. Mr. Oliviero owns over 24,610 units of Checkpoint Therapeutics Inc stock worth over $4,369,546 and over the last 8 years he sold CKPT stock worth over $1,139,087. In addition, he makes $2,308,250 as President, Chief Executive Officer a Director at Checkpoint Therapeutics Inc.
James has made over 9 trades of the Checkpoint Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 24,610 units of CKPT stock worth $50,451 on 26 June 2024.
The largest trade he's ever made was selling 276,000 units of Checkpoint Therapeutics Inc stock on 17 June 2022 worth over $300,840. On average, James trades about 34,350 units every 73 days since 2016. As of 26 June 2024 he still owns at least 1,977,170 units of Checkpoint Therapeutics Inc stock.
You can see the complete history of Mr. Oliviero stock trades at the bottom of the page.
James F. Oliviero III serves as President, Chief Executive Officer, Director of the Company. Mr. Oliviero joined our Board of Directors in October 2018 and has served as our Chief Executive Officer and President since October 2015. Mr. Oliviero has over twenty years of operational experience in the biotechnology industry. From May 2003 to September 2015, Mr. Oliviero served in a variety of leadership capacities at Keryx Biopharmaceuticals, Inc., a publicly traded biotechnology company, most recently as its Chief Financial Officer since April 2009, where he was instrumental in the growth of the company to a market capitalization over $1 billion. During his tenure at Keryx, Mr. Oliviero oversaw all finance, accounting, investor relations, corporate governance, business development and legal matters, as well as a leading member of the design of several clinical studies and the regulatory oversight of Keryx’s new drug application for Auryxia®, which successfully obtained FDA marketing approval in 2014 and also gained EMA marketing approval. Also while at Keryx, Mr. Oliviero completed over $500 million in various public financings for the company. Prior to Keryx, from August 1999 to May 2003, Mr. Oliviero was Director of Finance for ACCESS Oncology, Inc., a privately held biotechnology company. Mr. Oliviero began his professional career as an investment banker at Furman Selz LLC in New York City. Mr. Oliviero is a CFA charterholder and holds a B.B.A. in Finance with Highest Distinction from Emory University’s Goizueta Business School. Based on Mr. Oliviero’s biotechnology and pharmaceutical industry experience, as well as his extensive management experience, the Board of Directors believes that Mr. Oliviero has the appropriate set of skills to serve as a member of the Board.
As the President, Chief Executive Officer a Director of Checkpoint Therapeutics Inc, the total compensation of James Oliviero at Checkpoint Therapeutics Inc is $2,308,250. There are no executives at Checkpoint Therapeutics Inc getting paid more.
James Oliviero is 44, he's been the President, Chief Executive Officer a Director of Checkpoint Therapeutics Inc since 2018. There are 7 older and 2 younger executives at Checkpoint Therapeutics Inc. The oldest executive at Checkpoint Therapeutics Inc is Lindsay Rosenwald, 65, who is the Director.
James's mailing address filed with the SEC is 95 SAWYER RD, SUITE 110, , WALTHAM, MA, 02453.
Over the last 8 years, insiders at Checkpoint Therapeutics Inc have traded over $1,535,168 worth of Checkpoint Therapeutics Inc stock and bought 200,000 units worth $356,000 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss a James F Iii Oliviero. On average, Checkpoint Therapeutics Inc executives and independent directors trade stock every 94 days with the average trade being worth of $93,898. The most recent stock trade was executed by James F Iii Oliviero on 26 June 2024, trading 24,610 units of CKPT stock currently worth $50,451.
checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr
Checkpoint Therapeutics Inc executives and other stock owners filed with the SEC include: